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ABSTRAK 
POLIMORFISME GENETIK DALAM CYP2A6: IMPLIKASI UNTUK PERBEZAAN 
METABOLISME NIKOTINA ANTARA INDIVIDU 
Terdapat pelbagai bentuk CYP2A6. la memetabolismekan nikotina, kotinina dan 
sesetengah pro-karsinogen serta drug. Variasi dalam aiel CYP2A6 boleh 
mengurangkan risiko untuk merokok dan frekuensi bagi 'PM' adalah lebih rendah 
dikalangan penduduk Barat (Caucasion) berbanding penduduk Asia. Objektif 
kajian kami adalah untuk membangunkan kaedah genetik molekul dan analitikal 
bagi mengkaji kepelbagaian CYP2A6 di Malaysia. Subjek terdiri daripada dewasa 
yang sihat berketurunan Melayu, Cina dan India yang telah bersetuju menyertai 
kajian ini. DNA yang telah diesktrak daripada darah menggunakan kaedah 'salting-
out' seterusnya digunakan untuk mengesan genotip CYP2A6 melalui kaedah PCR. 
Seramai 616 subjek telah menyertai kajian ini. Frekuensi bagi CYP2A6*1A, 
CYP2A6*1B, CYP2A6*4, CYP2A6*5, CYP2A6*7, C YP2A 6*8, CYP2A6*10 dan 
CYP2A6*1x2 dikalangan etnik Melayu masing-masingnya adalah 27.04%, 
46.67%, 7.04%, 0.93%, 4.26%, 5.00%, 4.26% dan 0.37%, etnik Cina, 34.30%, 
44.48%,4.94%,1.16%,6.98%, 1.45%,1.74% dan 1.45% dan etnik India 52.01%, 
39.37%, 0.29%, 1.15%, 1.44%, 0.86% and 0.86%. CYP2A6*3 ditemui dikalangan 
etnik India sahaja. Kami juga menggunakan kaedah HPLC untuk mengukur 
kepekatan nikotina dan kotinina di dalam plasma dikalangan 40 sukarelawan yang 
telah mengunyah gam nikotina. Plot log probit nisbah metabolik telah diperolehi. 
xv 
Kewujudan beberapa sub populasi mencadangkan wujudnya k epelbagaian p ada 
lokus CYP2A6. Sebagai kesimpulan, kami telah berjaya membangunkan kaedah 
untuk mengkaji kepelbagaian CYP2A6 dikaiangan populasi di Malaysia. Kaedah 
PCR alel-spesifik yang kami bangunkan bukan sahaja spesifik dan sensitif, malah 
lebih mudah berbanding kaedah di dalam literatur. Kaedah ini telah digunapakai ke 
atas tiga etnik terbesar di Malaysia dan kami dapati kepelbagaian dalam 
polimorfisme CYP2A6 dengan CYP2A6*3 hanya ditemui dikalangan etnik India. 
Kaedah HPLC juga spesifik dan sensitif. lanya dibuktikan dengan membuat ujian 
pengesahan melalui kontrol yang telah ditetapkan dan juga projek rintis dengan 40 
subjek yang telah diketahui polimorfisme CYP2A6nya. Perbezaan genotip di 
antara etnik meramalkan penduduk Malaysia mungkin berbeza dari segi 
kecenderungan mengalami sesetengah penyakit dan juga kesan sampingan 
sesetengah drug. Walau bagaimanapun, kajian lebih lanjut perlu dilakukan dengan 
menggunakan saiz sampel yang lebih besar. 
Katakunci: CYP2A6, polimorfisme, PCR, genotip, HPLC, nikotina, kotinina, Melayu, 
Cina, India, penduduk Malaysia. 
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ABSTRACT 
GENETIC POL YMORPHISMS IN THE CYP2A6: IMPLICATIONS FOR INTER-
INDIVIDUAL DIFFERENCES IN NICOTINE METABOLISM 
CYP2A6 is polymorphic. It metabolizes nicotine, cotinine, several pro-carcinogens 
and drugs. Variant CYP2A6 alleles reduced risks for smoking and Caucasian have 
lower frequencies for the PM phenotype than Asians. The objective of our study 
was to develop analytical and molecular genetic methods for studying CYP2A6 
polymorphism in Malaysia. Subjects were healthy adult Malays, Chinese and 
Indians who gave informed consents. DNA was extiacted from blood using salting 
out procedures and subjected to PCR-genotyping for CYP2A6. Six-hundred and 
sixteen subjects were enrolled. The frequencies for CYP2A6*1 A, CYP2A6*1 B, 
CYP2A6*4, C YP2A 6*5, CYP2A6*7, C YP2A 6*8, CYP2A6*10 and CYP2A6*1x2 
among Malays were 27.04%, 46.67%, 7.04%, 0.93%, 4.26%, 5.00%, 4.26% and 
0.37% respectively; among Chinese, 34.30%, 44.48%, 4.94%, 1.16%, 6.98%, 
1.45%, 1.74% and 1.45% respectively and among Indians were 52.01%,39.37%, 
0.29%, 1.15%, 1.44%, 0.86% and 0.86% respectively. CYP2A6*3 was also 
detected among Indians. We also used an HPLC to determine nicotine and 
cotinine from plasma of 40 volunteers administered nicotine. A probit plot of log MR 
for nicotine was obtained. Sub populations exist suggesting existence of a 
polymorphism at the CYP2A6 locus. We conclude that we successfully developed 
xvii 
methods for the population study of CYP2A6 polymorphism in Malaysia. Our allele-
specific PCR was not only specific and sensitive but was also less tedious 
compared to published methods. Applied to the three major ethnic groups in 
Malaysia we noted heterogeneity in the polymorphism and the presence of 
CYP2A6*3 among Indians. Our HPLC methods were sufficiently specific and 
sensitive as proven by validating against seeded controls and using in a p!/ot 
project with 40 subjects in whom CYP2A6 polymorphism was evident. The ethnic 
differences we showed in our Malaysian population may imply different ethnic 
susceptibility to certain diseases and adverse effects of drugs. Further studies are 
however required using larger sample sizes. 
Keywords: CYP2A6, genetic polymorphism, PCR, genotypes, HPLC, nicotine, 
cotinine, Malays, Chinese, Indians, Malaysian 
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Chapter One 
Introduction and Review of the Literature 
1.1 Introduction 
No two individuals are the same. Great variability occurs. In as much as 
individuals differ in hair colour, their skin colour or their heights, they also differ 
in the way they react to medications and environmental toxins. Thus, when two 
individuals are given the same dose of the same drug, the first may obtain the 
best of effects while the other may develop toxicity and indeed may suffer 
death. Similarly when different individuals are exposed to the same 
environmental toxins some may suffer no harm while others may develop 
environmentally-induced diseases. 
Factors that contribute to the variability of pharmacologic response are 
many and varied. Well known are underlying disease of the individuals; drugs 
and food that are concurrently taken may cause interactions; his age, nutritional 
status, renal and liver function, and his concomitant other illnesses and 
exposures. 
Increasingly recognized as a factor of paramount importance in 
pharmacologic variability is the effect of inherited differences. It is well known 
that disease development is influenced by familial factors. For instance there is 
an aggregation of diseases like hypertension, diabetes mellitus, bronchial 
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asthma and even alcohol addiction in certain families. More recently, interest on 
similar inherited difference contributing to pharmacologic variability is gaining 
recognition. 
Among the first clinical observations of such inherited differences were 
documented in the 1950s. It was shown that prolonged muscle relaxation after 
suxamethonium was associated with an inherited deficiency of plasma 
cholinesterase (1999). It was similarly shown that the haemolysis occurring 
after the administration of the anti-malarial drug primaquine and the ingestion of 
fava beans was due to an inherited deficiency of glucose-6-phosphate 
dehydrogenase (G6PD)(Carson et al., 1956), and peripheral neuropathy with 
isoniazid occurred with inherited differences in acetylation of this medication 
(Evans and Reiling, 1999). It thus became increasingly evident that genetic 
variability of certain enzymes significantly contributed to pharmacologic 
variability and adverse drug reactions. "Pharmacogenetics" was born. 
"Pharmacogenetics," is a study which initially focused on the genetic 
polymorphisms, drug-metabolizing enzymes (DME's) and how this is translated 
into inherited differences in drug effects. Its definition is now refined as "the 
study of the hereditary basis for differences in a population's response to a 
drug" reflecting the multitudes of genetic variations that can impact on drug 
effects at population levels. In general, two types of pharmacogenetic 
conditions can be differentiated: first, genetic conditions transmitted as single 
factors altering the way drugs act on the body (altered drug action); and 
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second, genetic conditions transmitted as single factors altering the way the 
body acts on drugs (altered drug metabolism) (Eichelbaum and Evert, 1996). 
The term "pharmacogenetics" owed its origin to Vogel and Motulsky who 
coined the term 'pharmacogenetics' to describe genetically determined 
variations in drug response (Eiche!baum and Evert, 1996). These 
pharm8cogenetic conditions can occur either as rare defects or a 
polymorphism. "Genetic polymorphism" defines a monogenic trait that exists in 
the population in at least two phenotypes (and presumably at least two 
genotypes), neither of which is rare (Le. the rarest phenotype still occurs at the 
frequency of at least 1 %). 
Genetic polymorph isms have been described for a wide variety of drug 
and xenobiotic metabolizing enzymes. Many of these variations were first 
identified by the occurrence of adverse reactions after normal doses of drugs in 
patients or volunteers. They are indeed common occurrences. Mutations in the 
genes for numerous drug-metabolizing enzymes cause enzyme variants with 
higher or lower activity or lead to the partial or total absence of an enzyme 
protein. 
At the molecular level, inherited differences in drug-metabolizing capacity 
are generally monogenic traits. Their influence on the pharmacokinetics and 
pharmacologic effects of medications is determined by their importance for the 
activation or inactivation of drug substrates or their progenies. In general, the 
effects can either be profound toxicity for active medications that have a narrow 
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therapeutic index and are inactivated by a polymorphic enzyme (for example, 
mercaptopurine, azathioprine, thioguanine, and fluorouracil) (Krynetski and 
Evans, 1998) or reduced efficacy of medications that require activation by an 
enzyme exhibiting genetic polymorphism (such as codeine) (Desmeules et al., 
1991 ). 
In the last half a century, interest in pharmacogenetics, especially the 
association between decreased drug clearance and decreased activity of a 
drug-metabolizing enzyme, the inherited nature of the deficiency, and its 
frequency and clinical importance rapidly gained ground. Researchers compete 
to evaluate these phenomena. Prior to advances in molecular genetic 
techniques, phenotyping methods involving administration of probe drugs and 
measurement of metabolites in body fluids or determination of enzyme activity 
in families and populations were used extensively. It involves the use of in vivo 
probe drugs that are metabolized by single polymorphically expressed GYPs to 
one or more metabolites. To characterize GYP2D6 for instance, debrisoquine 
which is metabolised to 4-hydroxydebrisoquine, is used. To characterize 
CYP2A6, nicotine is used. It produces cotinine. To characterize GYP2C8 
amiadoquine is used. The administered drug and its metabolites are usually 
measured in plasma, saliva or urine permitting measurement of parent-to-
metabolite ratios in plasma (single or multiple time points) or urine (4 to 12 hour 
collection) (Spina et al., 1997, Gonzalez and Idle, 1994). In high throughput 
studies, multiple probes are administered as "cocktails", so that the activity of 
different GYPs can be measured simultaneously. 
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Phenotyping methods were and remain popular. For examples, there are 
abundant examples in the literature on the use of phenotyping in population 
studies. Phenotyping for CYP2D6 and CYP2C19 are the best characterized. 
For CYP2C19, phenotyping is usually with mephenytoin because the 4'-
hydroxylation of (S)-mephenytoin is catalyzed by CYP2C19 exclusively. The 
(S)-mephenytoin/(R)-mephenytoin ratio ("S/R ratio") in urine, recovery of 4'-
hydroxy mephenytoin in urine (8 hr), or a "hydroxylation index" (molar dose of 
(S)-mephenytoin divided by the molar amount of 4'-hydroxy mephenytoin 
recovered in urine) are used as measures of CYP2C19 activity and phenotype 
(Streetman eta/., 2000). Such studies revealed thatthe incidence ofPMs in 
various Caucasian populations of European decent varied from 0.9% to 7.7% 
(mean of 2.9%) compared to 13-23% (Ibeanu et a/., 1998) in Oriental 
populations. "Metabolic ratios" (MRs) for proguanil (proguanil! cycloguanil ratio 
in urine) and omeprazole (5-hydroxy omeprazole/omeprazole ratio in plasma) 
have also been used as indices of CYP2C19 phenotype (Streetman et a/., 
2000). 
The 2-hydroxylation of desipramine, 4-hydroxylation of debrisoquine, 0-
demethylation of dextromethorphan, oxidation of sparteine, and hydroxylation of 
metoprolol are all catalyzed by CYP2D6 and these reactions have been used to 
phenotype subjects for CYP2D6 polymorphism. The desipramine concentration 
and metoprolol/a-hydroxy metoprolol ratio methods require plasma, while urine 
and saliva (dextromethorphan) samples are used in debrisoquine/4-hydroxy 
debrisoquine, sparteine/ (2, 3- and 5, 6-dehydrosparteine methods) (Streetman 
et a/., 2000). With these methods (Streetman et a/., 2000, Bertilsson, 1995), it 
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has been shown that the incidence of PM subjects in Caucasian and Oriental 
populations averages 7% and 1 %, respectively. 
Interest in the molecular mechanism for the polymorphisms soon 
emerged. With the advent of molecular genetics, during the past several years, 
several of these polymorphisms have been studied at the protein and gene 
level. r,,1any laboratories including ours subsequently developed simple DNA 
tests to predict the phenotypes. Thus, in its humble beginning genetics 
depended on family studies but more recently, when molecular genetics began 
to be used, it allowed the investigation of DNA sequences that cause the 
difference. This change of the science of genetics has also much affected 
pharmacogenetics. In t he not too distant pasts, differences in drug response 
between ethnic populations were often called cross-cultural differences, 
especially by psychiatrists, who could not believe a genetic cause of the 
observed differences. 
Historically, initial work to elucidate the molecular genetic basis for 
inherited traits in pharmacology began in the late 1980s, with the cloning and 
characterization of a human gene encoding the drug-metabolizing enzyme 
debrisoquine hydroxylase (CYP2D6), a prototype of genetically polymorphic 
drug metabolising enzyme (Gonzalez et al., 1988). Genes are considered 
functionally "polymorphic" when stable allelic variants exist in populations, one 
or more of which alters the activity of the encoded protein in relation to the wild-
type sequence. In many cases, the genetic polymorphism is associated with 
reduced activity of the encoded protein, but there are also examples where the 
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allelic variant encodes proteins with enhanced activity. Since the cloning and 
characterization of CYP2D6, human genes involved in many such 
pharmacogenetic traits have been isolated, their molecular mechanisms have 
been elucidated, and their clinical importance has been more clearly defined. 
Molecular methods have many advantages. Genotyping methodologies 
can be easier to use than biochemical measurements in a clinical setting. They 
are less invasive. Genotyping requires only a single sample, whereas 
biochemical measurements often require various body fluids and/or tissue 
biopsies taken at multiple time points. Genotyping yield the same results across 
different laboratories, thus making it ideally suited to a diagnostic application 
(Kashuba et a/., 1998); in contrast, phenotyping may yield more variable data 
between laboratories and at different time points for the same patient. Intra-
individual variation does not exist in genotype data; on any given day a patient's 
genotype will be exactly the same. Furthermore, often a very small amount of 
material, such as blood from a single finger prick or a buccal swab, is all that is 
needed to complete genotyping assays. Genotyping results can also often be 
obtained more quickly than phenotyping results, and future technologies may 
offer rapid "bedside" assessment. 
Genotyping is more stable. It is not influenced by drug-drug interactions, 
or food-drug interactions. There are no problems with compliance or occurrence 
of adverse drug reactions among the test subjects, simplifying ethical 
considerations. It is also relatively easy to perform with samples of genomic 
DNA from either tissue, leukocytes, buccal swabs, fingernails and hair. 
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Characterization is through the use of different assay methods like PCR-
restriction fragment length polymorphism (RFLP), allele specific PCR, 
fluorescent dye-based genotyping, mass spectrometry, and gene chip 
technology (Shi et al., 2001, Cronin et al., 2001, Bertilsson, 1995, Linder and 
Vales, 1999). It is also possible to obtain genotype data for multiple CYPs, or 
different allelic variant forms of the same CYP, using a single sample of DNA 
(Tamminga et al., 2001). PCR-based genotyping is used extensively to 
investigate the genetic mechanism of the genetic polymorphisms in different 
populations, r aces and ethnic groups such as African-Americans, C aucasian-
Americans, Caucasian-Europeans (Northern and Southern), Japanese, 
Chinese, African and Canadian Native Indian and even Malaysians, like in this 
study. 
The developed technologies have also yielded very interesting 
observations of interethnic differences in pharmacogenetics. Phenotyping 
studies have previously clearly revealed interethnic and population differences 
in pharmacogenetics. At the molecular level, the differences have been more 
clearly defined. Differences in the types and frequencies of alleles are for 
instance observed with two of the allelic forms of CYP2D6 (CYP2D6*4 and 
CYP2D6*10). In Chinese, CYP2D6*4 is rare or occurs at low frequencies but is 
relatively more common in the West. On the other hand, CYP2D6*10 is a 
predominantly Oriental allele (Gaedigk, 2000). Similarly, clinically relevant 
interethnic differences in CYP2C9 genotype have been observed, where the 
allele frequency of CYP2C9*2 (8 to 14%) and CYP2C9*3 (6 to 16%) varies in 
different Caucasian populations (Garcia-Martin et al., 2001, Aynacioglu et al., 
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1999, Yasar et al., 1999, Nasu et al., 1997}. These alleles occur very rarely or 
at very low frequencies in Japanese and other Orientals (Nasu et al., 1997). 
The recent completions of the Human Genome Project have further 
changed the face of genetics, creating genomics and pharmacogenomics, 
where high technology is blended with pharmacogenetics. Whereas 
pharmacogenetics was based on biochemistry, the new pharmacogenomics 
takes advantage of high throughput DNA sequencing, gene mapping, and 
bioinformatics. The result will be a quantum leap in the ability to discover genes, 
whether they are for physical attributes, disease susceptibility, or the response 
to drugs. By understanding which genetic factors are responsible for whether a 
patient will benefit from a drug or toxin or be at risk for a particular side effect, it 
is possible to develop tests to predict these responses before exposure to the 
drug or toxin. 
1.2 Drug Metabolizing Enzymes (OMEs) 
In the above section, drug metabolising enzymes, chemical entities that have 
great influence on pharmacologic variability were extensively referred to. 
Genera"y, chemical compounds foreign to living organisms are actively 
metabolized by enzymatic reactions. Collectively, these enzymes are called 
xenobiotic or drug metabolizing enzymes (OMEs). Their evolution is most 
definitely not related to the human use of drugs as we know it today. Their 
evolution was probably related to the 'wars' life had to fight when it moved from 
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the sea to the land. And they are most important in causing variability in human 
exposures to exogenous substances. 
An ancestor of one of the DME families, cytochrome P450, probably 
arose some 1.5 billion years ago in primitive organisms. Hundred millions of 
years later, animals moved from water to land and began to use plants as diet. 
To protect themselves, plants developed phytotoxins, toxins that repel animals. 
Animals in turn, adapted to these toxins by generating a system to metabolise 
them and rendered them less harmful. The prehistoric P450 genes evolved into 
many families and subfamilies, thought to be a response to the great variety of 
toxins present in the diet and ambient surroundings (Gonzalez and Nebert, 
1990). With further move into land, and under the pressure of natural selection, 
due to the accumulating mutations, deletions, duplications and other changes, 
P450 families exhibit considerable interspecies and inter-individual variation 
that later became I characteristics' to the species and t heir localities and now 
understood to be the root to geographical difference in pharmacology of drugs 
and toxins. 
The principal function of DMEs is to metabolise the large number of 
endogenous and exogenous compounds. In human, they are importantly 
involved in the biotransformation of exogenous agents, such as drugs and 
solvents and they also are involved in the activation of pro-carcinogens to 
carcinogens (Pelkonen and Raunio, 1997). Although their physiologic role is not 
fully elucidated, they also participate in the synthesis and degradation of several 
steroid hormones and other small molecular endogenous compounds. 
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Metabolism usually results in the inactivation of the parent compound 
(metabolic activation) (Nebert, 1997a) but in some cases, as with pro-
carcinogens, active products are formed. 
The clinical consequence of the conversion therefore varies. Whether a 
genetic polymorphism has relevance for drug therapy depends on the 
r;hClracteristics of the drug in question. The quantitative role 0 faD ME in the 
overall kinetics of a drug and the agent's therapeutic range will determine how 
much the dose has to be adjusted in poor metabolisers or ultrarapid 
metabolisers. The example of the CYP2D6 polymorphism provides clinical 
evidence for these ideas. Most patients (about 90%) require 75-150 mg/day of 
nortriptylline to reach a "therapeutic" plasma steady-state concentration of 200-
600 nmollL, but poor metabolisers need only 10-20 mg/day to reach the same 
concentrations. Ultrarapid metabolisers, on the other hand, may require 300-
500 mg/day or even more to reach the same plasma concentration. Obviously, 
if the genotype or phenotype of the patient is not known, poor metabolisers will 
be overdosed and be at high risk of drug toxicity, whereas ultrarapid 
metabolisers will be under-dosed (Bertilsson et al., 1997, Dalen et al., 1998). 
On the other hand, for drugs like codeine and enalapril, metabolism produces 
the active compounds required for efficacy and individuals lacking in the 
particular enzyme will not enjoy the benefits of the prescribed drugs. Of a 
further interest, almost all exogenous carcinogens require activation by 
metabolic enzymes, and detoxification enzymes frequently exist to deactivate 
carcinogens or their intermediate metabolites. Inherited polymorphisms in these 
enzymes may alter their rate of activation or detoxification, thus increasing or 
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decreasing the carcinogenic potential of the environmental exposures they act 
on. 
Most drugs initially possess lipophilic characteristics that promote the 
passage of the drug through cell membranes to its site of action. Lipophilic 
drugs must be bio transformed into more hydrophilic metabolites to facilitate 
elimination and excretion. The cytochrome P450 system (CYP) is responsib!a 
for metabolizing many endogenous and exogenous substances, including 40% 
to 50% of all medications (Ingelman-Sundberg et al., 1999), into more 
hydrophilic substances. Overall, approximately 10 P450s are responsible for the 
metabolism of a large number of pharmacologic agents in humans. 
DMEs are categorised into two groups, i.e., phase I (functionalisation 
reactions) and phase II enzymes (conjugation reactions) (Nebert and Gonzalez, 
1987). Phase I enzymes mediate the first step in the metabolism of xenobiotics 
into more hydrophilic forms. These enzyme families are categorised by their 
ability to metabolise different substrates (Guengerich, 1992). 
P450 enzymes are phase I enzymes that catafyse the mono-oxidation or 
reduction and epoxidation of their substrates. Hydroxylases, flavin-containing 
mono-oxygenases (FMOs) and mono-aminoxidases (MAOs) are other phase I 
enzymes (Nebert, 1994). These enzymes add small molecules (e.g., OH- or 0-
groups) to their substrates. The metabolism of xenobiotics occurs mainly in liver 
(Daly et al., 1993). 
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Phase II enzymes usually detoxify, but sometimes also activate, 
endogenous or exogenous compounds. The substrate is converted into more 
hydrophilic form by conjugating with, for instance, glutathione. Very lipophilic 
compounds are usually first metabolised by phase I enzymes and then by 
phase II enzymes, whereas less lipophilic compounds can be metabolised 
directly by phase II enzymes. Phase II enzymes are categorised as glucuronyl 
transferases (UGTs), su!fotransferases (SUL Ts), glutathione-S-transferases 
(GSTs) and N-acetyltransferases (NATs). Many phase" enzymes have been 
shown to exhibit genetic polymorphisms (Mackenzie et al., 1997, Nebert, 
1997b, Pelkcnen et al., 1998, Hirvonen, 1999). For example, the GSTM1 
enzyme has been found to be polymorphic, and a total gene deletion (GSTM1-1 
nUll) has been suggested to be a risk factor in lung cancer caused by tobacco 
smoke (London et al., 1995, Weinberg and Sandler, 1999, Bennett et al., 1999). 
GSTs metabolise aflatoxin B 1, PAHs, and some other compounds present in 
tobacco smoke. 
1.3 What is Cytochrome P450? 
Cytochrome P450 is a cellular chromophore that was first named in 1961, 
because the pigment (P) has a 450 nm spectral peak when reduced and bound 
to carbon monoxide (Gonzalez, 1989). P450s comprise well characterized 
group of phase I enzymes. In endoplasmic reticulum (ER), a P450 enzyme 
together with appropriate cofactors, such as NADPH, metabolises chemicals by 
breaking up oxygen molecules. The chemical to be metabolised receives a 
hydroxyl group, while the other oxygen atom is inserted into a water molecule. 
This reaction is called mono-oxygenation (Degtyarenko and Archakov, 1993). 
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The active centre of the P450 enzyme contains heme, and the substrate is in a 
proper orientation with respect to the heme iron and oxygen molecule for the 
reaction to take place (Daly et a/., 1993). 
P450 is involved in the metabolism 0 f drugs, environmental pollutants, 
dietary chemicals and endogenous compounds (Nelson et a/., 1996). Since first 
described decades ago, tens of thousands scientific papers have been 
published on the P450. This is a clear reflection of the importance that the 
system plays in the metabolism of a wide range of both endogenous 
compounds and drugs. Initially the system was thought to be a single enzyme, 
but it soon became clear in the 1970's that there exists multiple forms of this 
haemoprotein, and they are products of discrete genetic loci. The organisation 
of the P450 superfamily into families and subfamilies has been reviewed on 
multiple occasions (Gonzalez, 1992, Nelson et a/., 1993, Archakov and 
Degtyarenko, 1993), but it has always been clear that understanding the role of 
individual forms of P450 in the metabolism of drugs would be a gigantic task, 
given the number and overlapping specificity of the enzymes involved. 
The P450 enzymes are widely distributed across species. It was not 
initially known that different species and tissues had similar isoforms. Names 
were assigned to the enzymes according to their spectral properties, 
electrophoretic mobility or their substrates. However, with new knowledge of the 
amino acid sequences for the enzymes, a general nomenclature based on the 
presence of common amino acid sequence was proposed by Nebert (Nelson et 
a/., 1996). This system groups the enzymes and genes into families and 
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subfamilies with the prefix 'CYP' to designate P450 enzymes in all species 
(except Drosophila and mouse gene where 'Cyp' is used). Fourteen families 
and 26 subfamilies exist in all mammals to date, 20 of the subfamilies have 
been mapped to the human genome (Benet et al., 1996). Families are defined 
as having more than 40% homology in their amino acid sequence and are 
designated by an Arabic numeral, and subfamilies have more than 55% 
analogy and are designated by a capital letter. An Arabic numeral after the 
letter denotes the individual enzyme and the gene associated with the enzyme 
is denoted in italics. For example, the CYP2 family (Ne!son et al., 1996, 
Slaughter and Edwards, 1995), has several subfamilies such as CYP2C, 
CYP2D and CYP2E. The individual enzyme is denoted by a numeral, as in 
CYP2D6, and the gene is denoted as CYP2D6. 
Three of the CYP families - CYP1, CYP2 and CYP3 - are the most 
important in metabolizing xenobiotics and have been intensively studied by 
toxicologists and biochemists. The largest and most complex of these is the 
CYP2 family, which consists of multiple subfamilies; in both the mouse and 
human genomes, individual genes within its subfamilies have similar sequences 
and are physically clustered (Nelson et al., 1993). 
That P450 is important in therapeutics is undeniable even though efforts 
are made to design the new generation of therapeutic agents that comprises a 
number of molecules of higher molecular weight which are not subject to 
oxidative metabolism. The fact remains that the most existing drugs and indeed 
many drugs 0 f t he future (Bossart and Pearson, 1 995, 0 iMasi, 1 995, Drews, 
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1995, Kleinberg and Vvanke, 1995, Macinnes et al., 1994, Smith, 1994) depend 
on, or will depend on the system to terminate their biological effect, or indeed 
cause their side effects or adverse reactions (Smith, 1994). 
As alluded above, P450 also plays established roles in the metabolic 
activation of carcinogens (Miller, 1994, Waller, 1994, Shubik, 1995). There is 
growing evidence that variability in P450 involved, qualitatively or quantitatively, 
may contribute to interindividual differences in cancer susceptibility (Wolf et al., 
1994, Gonzalez and Gelboin, 1994, Caporaso and Goldstein, 1995, Rannug et 
al., 1995). It is therefore important that the function of the individual forms of 
P450, together with their specificity and regulation, be understood for many 
reasons including the design of drugs with a more desirable pharmacokinetic 
profile and reduced toxicity, the detection of 'at risk' groups and the targeting of 
new therapeutic agents to specific metabolic pathways. Indeed recognition of 
the importance of these issues led to the establishment of a Human Liver Bank 
(Boob is et al., 1980). 
1.4 Why Study CYP2A6? 
CYP2 gene family-CYP2 is the largest P450 family in mammals. In human, 
CYP2C8, C YP2C9, C YP2C18, and C YP2C19 are the major 0 ME's and they 
together metabolise more than 50% of prescribed drugs. Other CYP's involved 
in drug metabolism include CYP2A6, CYP2A 13, CYP2B6, CYP2E 1, CYP2F1, 
and CYP2J2. 
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CYP2A6 was first identified as the human coumarin 7 -hydroxylase (Miles 
et al., 1990, Yamano et al., 1990, Yun et aI., 1991) and is now known to 
metabolise several compounds including nicotine (Messina et al., 1997), 
coumarin (Miles et al., 1990) and the anticancer tegafur (Ikeda et al., 2000). 
Apart from that, CYP2A6 also activates pro-toxins and procarcinogens, 
including many nitrosamines and aflatoxin B1 and several tobacco-specific 
nitrosamines (Fujita and Kamataki, 2001, Sellers et al., 2003). Some 
compounds have been found to inhibit CYP2A6 enzyme in vitro and they 
include methoxsalen (8-methoxypsoralen) (Koenings and Trager, 1998, Draper 
et al., 1997, MaEenpaEaE et al., 1993) , menthofuran (Khojasteh-Bakht et a/., 
1998), pilocarpine (Kimonen et al., 1995) and tranylcypromine. 
CYP2A6 is predominantly expressed in the liver (Koskela et a/., 1999). 
Expression of CYP2A6 mRNA is highly variable (Koskela et al., 1999) and this 
variation can be partly explained by the polymorphic nature of the CYP2A6 
gene. There is thus a pronounced interindividual and interethnic variability in 
CYP2A6 levels and activity. To date, at least 20 variants of the CYP2A6 gene 
and numerous single nucleotide polymorphisms (SNPs) (see 
http://www.imm.kLse/CYPalleles/cyp2a6.htm) have been described. 
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Adapted from (Raunio, 2001). SM-'12502, 3,5-dimethyi-2-(3-pyridyl)thiazolidin-
4-one hydrochloride; NNK, 4-methylnitrosamino-1-(3-pyridyl)-1-butanone; 
NDEA, N-nitrosodiethylamine; AFB1, aflatoxin 81; MOCA, 4,4k-methyienebis(2-
chloroaniline); DCBN, 2,6-dichlorobenzonitrile; MTBE, methyl tert-butyl ether, 
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1.5 Cigarette Smoking and CYP2A6 
Cigarette smoking is governed by the need to maintain desirable levels of 
nicotine in the body (Benowitz et al., 1998, Benowitz, 1996). Approximately 
80% of nicotine is C-oxidized to the inactive metabolite cotinine (Benowitz and 
Jacob, 1994); approximately 90% of this pathway is mediated by CYP2A6 
(Nakajima et al., 1996). In vitro studies using human liver microsomes and 
recombinant P450s have shown that CYP2A6 is the most important P450 
responsible for the C-oxidation of nicotine (Nakajima et al., 1996, Messina et 
al., 1997). 
CYP2A6 has a high-affinity for both nicotine and its oxidized metabolite 
cotinine. These have been revea!ed in studies with heterologously expressed 
CYP enzymes and human liver microsomes in vitro (Figure 1). The reaction is a 
two-step reaction in which nicotine is first oxidized to nicotine iminium ion and 
subsequently to cotinine by cytosolic aldehyde oxidase. The reaction rate is 
limited by the CYP2A6-mediated formation of nicotine iminium ion from nicotine 
but up to 80% of nicotine is metabolized to cotinine. Cotinine is turn, oxidized to 
several metabolites, also by CYP enzymes, including possibly CYP2A6 
(Murphy et al., 1999). At low physiologic concentration, CYP2A6 appears to be 
the only enzyme involved in the metabolism of nicotine (50 m M) but at high 
nicotine concentrations (SOD mM), other CYP isoforms, such as CYP2B6, may 
also playa part (Yamazaki et al., 1999). 
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Of further importance, individuals homozygous for a CYP2A6 gene 
deletion displayed only 15% of urinary cotinine levels compared with individuals 
carrying at least one active CYP2A6 gene after smoking the same number of 
cigarettes (Kitagawa et al., 1999). Because of the substantial involvement of 
CYP2A6 in nicotine elimination, it has been proposed that the CYP2A6 
polymorph:sm is a major determinant of an individual's smoking behaviour. 
Recently, the total inhibition of CYP2A6 function was also suggested to reduce 
smoking, and therefore may have a role in smoking cessation and tobacco 
exposure reduction (Sellers and Tyndale, 2000a, Sellers et al., 2000b). 
The first case-control study to determine the role of CYP2A6 in 
maintaining smoking was done in a Canadian population by Pianezza et al 
(1998). Results showed that at least one variant allele of the CYP2A6 reduced 
the risk to smoking (Pianezza et al., 1998). The defective genotype was 
similarly also found to reduce smoking (Rao et al., 2000). Contradictory results 
have however also been obtained. In a study on Americans by London et al. 
(1999) no evidence was found for an association between reduced CYP2A6 
activity and the number of cigarettes consumed per day in smokers. Similarly, 
Sabol and Hamer (1999) and Tan et al. (2000) found no correlation between the 
CYP2A6 genotype and cigarette smoking behaviour and further similar results 
were obtained in French and Finnish populations (Tiihonen et al., 2000, Loriot 
et al., 2001). 
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Tmns-3'-hydroxy cotinine Cotinine 
Figure 1.1 Participation of CYP2A6 in the oxidative metabolism of nicotine 
and cotinine 
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1.6 CYP2A6 Polymorphism and its Analysis by Polymerase Chain 
Reaction 
As alluded, CYP2A6 is genetically polymorphic. Phenotyping results revealed a 
pronounced inter-individual variability in the CYP2A6 activity (Rautio et al., 
1992, Cholerton et al., 1992, Iscan et al., 1994). In Caucasian populations, the 
poor metaboliser (PM) phenotype for CYP2A6 appears to occur at very low 
frequencies and very rarely are cases reported where individuals completely 
lacked CYP2A6 activity (Hadidi etal., 1997, Oscarson etal., 1998). On the 
other hand, the frequency of PMs for CYP2A6 among Japanese seems to be 
higher and in vitro studies using microsomes from Japanese subjects 
demonstrated that eight out of 30 livers had a very low or no CYP2A6 
immunoreactivity and activity (Shimada et al., 1996). 
The subfamilies CYP2A, CYP2B, CYP2F and CYP2S comprise a gene 
cluster on chromosome 19 (Kwon et al., 2001, Hoffman et al., 1995, Sheng et 
al., 2001, Rylander et al., 2001) with CYP2A comprising of CYP2A6, CYP2A7, 
CYP2A13, and more than 3 pseudogenes (Hoffman et al., 1995). CYP2A7 and 
CYP2A6 have 94% amino acid homology but CYP2A7 is functionally inactive 
(Yamano et al., 1990). CYP2A13 is highly homologous and although it is also 
able to metabolize coumarin, nicotine and tobacco-smoke nitrosamine, its role 
is limited in this (Su et al., 2000). 
Several variant alleles of the CYP2A6 gene have been characterized, 
beginning about 10 years ago when the sequences of the wild-type and one 
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variant allele were reported. The wild-type alleles CYP2A6*1A and CYP2A6*1B 
(containing 58 bp of CYP2A 7 in the 3'UTR) is a result of a conversion in the 3' 
flanking region of the gene but they are similar in enzymatic function (Oscarson 
et al., 1999a, Miyamoto et al., 1999). CYP2A6*2 encodes a protein with a 
L 160H substitution which does not incorporate heme and is inactive in vitro 
(Inoue et al., 2000) and in vivo (Benowitz et al., 1995, Hadidi et aI., 1997). 
CYP2A6*3, originally thought to be a true variant allele, has later been shown to 
be lacking in different populations (Oscarson et al., 1999b). One reason for the 
original misclassification turned out to be due to the very common CYP2A6*1 B 
allele exhibiting a gene conversion between 3' flanking regions of the CYP2A6 
and CYP2A7 genes (Oscarson et al., 1999a). Consequently, CYP2A 7 
sequences are also amplified when the original genotyping method was used 
(Salguero et a/., 1995), causing misclassification. Nevertheless, CYP2A6 *3 
may indeed be a true but an inactive and rare allele created by multiple 
sequence conversions between CYP2A6 and CYP2A7 (Salguero et a/., 1995). 
The occurrence of multiple gene and pseudogene duplications, high sequence 
homology, and the gene conversion events in CYP2A6 loci, have led to the 
originally erroneous genotyping methods (Salguero et a/., 1995). This lead to 
misidentification of CYP2A 7 as C YP2A 6*2, and CYP2A6*1 B as CYP2A6*3 
alleles. Several other CYP2A6 alleles have been created by the unequal 
crossover events. Thus, the CYP2A6*4A deletion allele is generated by an 
unequal crossover between the 3' flanking regions of the CYP2A6 and CYP2A7 
genes. Similarly, In the CYP2A6*4D allele, the crossover region occurs in intron 
8 or exon 9 (Oscarson et a/., 1999b). Two point mutations (CYP2A6*2 and 
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CYP2A6*5) abolish the catalytic activity of the encoded enzyme, similar with the 
gene deletions (Yamazaki et al., 1999, Oscarson et a/., 1999a). 
The frequency of the inactive alleles is low in European populations and 
very few poor metabolisers for the probe drug coumarin have been described in 
these population. In contrast, a relatively high allele frequency (15-20%) of the 
CYP2A6 gene deletion has been found in Asians, resulting in a generally 
reduced activity in these populations. 
Basic to the study of the genetic polymorphism of DMEs is the availabiiity 
of methods to identify the variations. Therefore to study the genetic 
polymorphism of CYP2A6 specific detection of CYP2A6 allelic variants would 
be useful to study human populations for the presence of alleles that predict 
variable responses. 
A variety of genotyping techniques have been developed to identify 
polymorphisms. Commonly used methods include gel electrophoresis-based 
techniques, such as polymerase chain reaction (PCR) coupled with restriction 
fragment length polymorphism (RFlP) analysis, multiplex PCR, and allele-
specific amplification. Fluorescent dye-based high-throughput genotyping 
procedures have gained increased popularity, including the oligonucleotide 
ligation assay (OlA), heterozygote sequencing, TaqMan (Perkin Elmer, Foster 
City, C A) allelic discrimination, and high-density c hip array technology. Novel 
polymorph isms also can be identified by single-strand conformation 
polymorphism (SSCP) and direct heterozygote sequencing. Mass spectrometry 
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